Clinical trial experience with Functional Assessment of Cancer Therapy—Lung in conventional and targeted non—small cell lung cancer therapy

Heyes, Anne

doi:10.1053/j.seminoncol.2004.04.009

Cited by 6 publications

(12 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although many studies have used FACT-L assessment during chemotherapy for advanced NSCLC, data on differences between treatment groups are limited [45,46]. Nonetheless, clinical trials have shown that chemotherapy provides QOL benefits over supportive care in patients whose lung cancer responds or stabilizes in response to chemotherapy, perhaps through symptom palliation and improvement in physical function [14].…”

Section: Qol In First-line Treatment Of Lung Cancermentioning

confidence: 99%

Quality-of-Life Considerations in Patients with Advanced Lung Cancer: Effect of Topotecan on Symptom Palliation and Quality of Life

Gralla¹

2004

The Oncologist

View full text Add to dashboard Cite

Key goals in the treatment of lung cancer are to improve both survival and quality of life (QOL). While formal techniques are frequently used to evaluate survival and response, such rigor is used less often in assessing the impact of treatment on quality of life. Many patients with lung cancer are elderly and have complex medical histories and a myriad of comorbidities. In these patients, with limited survival expectations, symptom palliation, quality of life, and convenience of therapy are especially important end points. Indeed, clinical trials are now incorporating symptom scores and QOL outcomes in their designs (now combined as "patient reported outcomes" or PROs). Moreover, symptom palliation correlates well with QOL and survival duration, providing further rationale for therapy selection based on these parameters. The potential palliative and QOL benefits of chemotherapy have been investigated for several agents in lung cancer trials. The Oncologist 2004;9(suppl 6):14-24 www.TheOncologist.com Correspondence: Richard J. Gralla, M.D., New York Lung Cancer Alliance, 459 Columbus Avenue (PMB-187), New York, New York 10024-5129, USA. Telephone: 212-579-6084; Fax: 801-365-6442; e-mail: rgralla@att.net Received October 4, 2004; accepted for publication October 9, 2004. ©AlphaMed Press 1083-7159/2004 The Oncologist ® LEARNING OBJECTIVESAfter completing this course, the reader will be able to:1. Explain the rationale for evaluating quality of life as a treatment end point.2. Describe the multidisciplinary dimensions incorporated into validated quality-of-life questionnaires.

show abstract

Section: Qol In First-line Treatment Of Lung Cancermentioning

confidence: 99%

Quality-of-Life Considerations in Patients with Advanced Lung Cancer: Effect of Topotecan on Symptom Palliation and Quality of Life

Gralla¹

2004

The Oncologist

View full text Add to dashboard Cite

show abstract

“…Twelve studies employed symptom palliation as the primary outcome [ 7 , 10 , 12 , 13 , 15 - 22 ], while thirteen of the identified trials used QOL [ 8 , 10 - 17 , 19 - 22 ]. Ten of the identified articles used both symptom palliation and QOL as primary outcomes [ 10 , 12 , 13 , 15 - 17 , 19 - 22 ]. Two of the studies used neither symptom palliation nor QOL as primary endpoints, but rather as secondary endpoints [ 9 , 23 ].…”

Section: Resultsmentioning

confidence: 99%

“…The FACT- L was used in two of the reviewed studies [ 13 , 16 ]. It consists of general QOL questions that are divided into four categories: physical well-being, social/family well-being, functional well-being, and emotional well-being.…”

Section: Resultsmentioning

confidence: 99%

“…The symptoms assessed include coughing, dyspnea, chest pain, weight loss, anorexia, and clarity of thought. These various subscales allow QOL to be divided into different components for analysis [ 13 ].…”

Section: Resultsmentioning

confidence: 99%

“…Lastly, the trial outcome index (TOI) was used twice as a measure of performance status as well as a prognostic tool for survival [ 13 , 16 ]. It is also considered to be a strong measure of QOL as it is an alternative scoring of the FACT-L, which uses the sum of the FACT-L’s individual subscales [ 13 ]. It is a 21-item survey which takes into account the physical well-being, functional well-being, and lung cancer symptoms [ 16 ].…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

An Update on the Quality of Life Measurements in Lung Cancer Patients Receiving Palliative Radiotherapy: A Literature Review

et al. 2013

View full text Add to dashboard Cite

To conduct a systematic review on validated instruments used to assess quality of life (QOL) in patients with either primary or metastatic lung neoplasms. A literature search was conducted through the Embase (1950 - 2012 week 30) and Medline (1946 - 2012 week 3 July) databases. All compiled studies utilized QOL or symptom palliation as a primary or secondary outcome for patients with advanced lung cancer. A total of 17 studies met our criteria. Four questionnaires were most commonly used: the EORTC QLQ-C-30, the EORTC QLQ-LC-13, the Rotterdam Symptom Check-list (RSCL), and the Hospital Anxiety and Depression Scale (HADS). The limited number of studies assessing QOL in patients with advanced lung cancer suggests that QOL is still an uncommon endpoint for this patient population. Nine of seventeen (53%) studies evaluated QOL in their cohorts and out of those nine, seven (77%) included the use of a lung-specific tool. In total there were eleven of seventeen (65%) studies that evaluated symptom palliation, indicating the relevance of symptom palliation as an endpoint in this population. It is encouraged that lung specific QOL questionnaires, such as the FACT-L and the EORTC QLQ LC-13, be used in tandem with general questionnaires, such as the FACT-G and the EORTC QLQ C-30, in advanced lung cancer patients undergoing radiotherapy. Clinicians should also be advised to focus more on QOL assessment.

show abstract

Cancer symptom response as an oncology clinical trial end point

Bouchard

Aaronson

Gondek

et al. 2018

Expert Review of Quality of Life in Cancer Care

View full text Add to dashboard Cite

Introduction: A critical challenge in oncology is interpreting clinical trial results to inform clinical decision making. Clinical trials typically focus on overall survival (OS) and progression-free survival (PFS) as primary endpoints, which do not reflect early signs of meaningful patient benefit or harm. Cancer symptom response (CSR) can provide information about early treatment response, and studies show that CSR predicts long-term health outcomes. Areas covered: CSR requires careful consideration of its measurement and interpretation to facilitate integration into clinical practice. We describe considerations for the evaluation, analysis, and interpretation of CSR in clinical trials. To illustrate the potential clinical value of CSR, we performed a retrospective analysis of a three-arm randomized cooperative-group clinical trial. Expert commentary: Evaluation of CSR provides a meaningful assessment of early cancer treatment effects. It can act as an early signal of disease progression and death and thus can identify which patients with stable disease will have a more favorable prognosis. Future research will include development of methods for more accurate assessment of CSR, reduction of the number of symptoms used as signals for disease progression or survival by tumor type, and statistical methods that effectively correct for missing data and informative censoring.

show abstract

Clinical trial experience with Functional Assessment of Cancer Therapy—Lung in conventional and targeted non—small cell lung cancer therapy

Cited by 6 publications

References 9 publications

Quality-of-Life Considerations in Patients with Advanced Lung Cancer: Effect of Topotecan on Symptom Palliation and Quality of Life

Quality-of-Life Considerations in Patients with Advanced Lung Cancer: Effect of Topotecan on Symptom Palliation and Quality of Life

An Update on the Quality of Life Measurements in Lung Cancer Patients Receiving Palliative Radiotherapy: A Literature Review

Cancer symptom response as an oncology clinical trial end point

Contact Info

Product

Resources

About